Sandu Pharmaceuticals Ltd
Incorporated in 1985, Sandu Pharmaceuticals Ltd manufactures and trades Ayurvedic proprietary medicines.
- Market Cap ₹ 49.1 Cr.
- Current Price ₹ 50.8
- High / Low ₹ 69.5 / 43.8
- Stock P/E 33.4
- Book Value ₹ 42.3
- Dividend Yield 1.57 %
- ROCE 5.36 %
- ROE 3.66 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Promoter holding has decreased over last 3 years: -7.53%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|
65.50 | 65.35 | 67.28 | 67.78 | |
62.62 | 62.87 | 64.98 | 65.34 | |
Operating Profit | 2.88 | 2.48 | 2.30 | 2.44 |
OPM % | 4.40% | 3.79% | 3.42% | 3.60% |
0.08 | 0.33 | 0.42 | 0.41 | |
Interest | 0.11 | 0.08 | 0.06 | 0.08 |
Depreciation | 0.53 | 0.52 | 0.58 | 0.66 |
Profit before tax | 2.32 | 2.21 | 2.08 | 2.11 |
Tax % | 31.47% | 31.22% | 29.33% | |
1.59 | 1.52 | 1.46 | 1.47 | |
EPS in Rs | 1.80 | 1.57 | 1.51 | 1.53 |
Dividend Payout % | 41.56% | 0.00% | 52.93% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 23% |
3 Years: | -11% |
1 Year: | -17% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 4% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 8.81 | 9.66 | 9.66 | 9.66 |
Reserves | 27.66 | 29.58 | 30.93 | 31.19 |
0.00 | 0.00 | 0.00 | 0.52 | |
12.81 | 14.93 | 11.82 | 13.76 | |
Total Liabilities | 49.28 | 54.17 | 52.41 | 55.13 |
16.00 | 16.62 | 17.88 | 18.17 | |
CWIP | 0.48 | 0.42 | 0.00 | 0.00 |
Investments | 9.11 | 9.65 | 10.42 | 11.69 |
23.69 | 27.48 | 24.11 | 25.27 | |
Total Assets | 49.28 | 54.17 | 52.41 | 55.13 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
0.95 | 0.22 | 0.76 | |
-5.47 | 0.54 | -1.31 | |
0.93 | 0.58 | -0.72 | |
Net Cash Flow | -3.59 | 1.34 | -1.27 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Debtor Days | 22.23 | 26.75 | 26.42 |
Inventory Days | 115.06 | 167.70 | 137.28 |
Days Payable | 69.63 | 98.30 | 47.07 |
Cash Conversion Cycle | 67.67 | 96.15 | 116.63 |
Working Capital Days | 42.41 | 52.33 | 56.69 |
ROCE % | 6.05% | 5.36% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
15m - Sandu Pharma confirms non-applicability of SEBI Large Corporate Framework as of March 31, 2025.
-
Announcement Under Regulation 30(LODR)-Update-Intimation For Change In The Email Address And Website Address Of The MUFG Intime India Private Limited, Our Registrar And Share Transfer Agent ('RTA')
2d - Change in email and website of registrar and share transfer agent.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 5 Apr
-
Disclosure As per Regulation 31(4) Of The SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011
3 Apr - Disclosure of share encumbrance status for FY 2025.
-
Closure of Trading Window
24 Mar - Closure of trading window from April 1, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:[1]
Company manufactures over 100 types of products, including oils, syrups, granules, powder, and avlehas, which are marketed under the Sandu brand viz, Sandu Ashoka Compound, Sandu Abhayarishta, Sandu Arvindasav, Sandu Balant Kadha No. 1, Sandu Debix Tablet, Sandu Bhunimbadi Kadha, Sandu Chandanasav Syrup, Sandu Chandraprabha, Sandu Chyavanprash Special, Sandu Dadimavaleha, etc.